Answers are grounded in this paper and cite their sources.
Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia represents a critical threat owing to its high mortality and antibiotic resistance. Near-infrared II (NIR-II) fluorescent photothermal therapy (PTT) enables deep-tissue heating but risks incomplete bacterial clearance and thermal damage. Symmetric donor-acceptor-donor (D-A-D) NIR-II molecules often suffer from high molecular weights, low fluorescence, and suboptimal photothermal conversion. Herein, we report asymmetric D-A-π-D NIR-II aggregation-induced emission luminogens (AIEgens) featuring a benzothiopyrylium acceptor, triphenylamine donors, and furan or thiophene as π-bridge. Furan strengthens non-covalent conformation locking while weakening intermolecular π-π stacking, thereby enhancing both fluorescence and photothermal performance. AIEgen 4fop achieves an optimal photothermal conversion efficiency of 84.3% and a NIR-II photoluminescence quantum yield of 2.31% in toluene. To boost antibacterial activity, 4fop was co-encapsulated with the thermally responsive NO donor BNN6 into Pluronic F-127 nanoparticles. In a murine pneumonia model, this nanoplatform substantially reduces bacterial burden, suppresses inflammation through TNF pathway modulation, and promotes lung repair. This work establishes a rational D-A-π-D design strategy and an integrated nanoplatform for the precise treatment of deep-seated drug-resistant infections.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: